HCV NS5A abrogates p53 protein function by interfering with p53-DNA binding

Table 1 HCV NS5A inhibits the transactivation of endogenous p53 on p21 promoter

Group	Relative luciferase activity	F	P
pwwp-luc (1 µg)
+ pCNS5A (0 µg)	3.49 × 105b	20.71	< 0.01
+ pCNS5A (0.5 µg)	2.69 × 105
+ pCNS5A (1.0 µg)	1.62 × 105
+ pCNS5A (2.0 µg)	0.58 × 105
pwwp-mut-luc (1.0 μg)
+ pCNS5A (0 µg)	0.60 × 105	0.76	> 0.05
+ pCNS5A (0.5 µg)	0.65 × 105
+ pCNS5A (1.0 µg)	0.62 × 105
+ pCNS5A (2.0 µg)	0.64 × 105

^bt = 5.92, P < 0.01.

Table 2 HCV NS5A inhibits exogenous p53 transactivation on p21 promoter

Group	Relative luciferase activity	F	P
pwwp-luc (1 µg)	0.47 × 105ab	24.23	< 0.01
+pC53-NS3 (1 µg)	5.63 × 105b
+pCNS5A (0.5 µg)	1.61 × 105
+pCNS5A (1.0 µg)	0.69 × 105
pwwp-mut-luc (1 µg)	0.45 × 105a	0.69	> 0.05
+pC53-NS3 (1 µg)	0.50 × 105
+pCNS5A (0.5 µg)	0.43 × 105
+pCNS5A (1.0 µg)	0.48 × 105

^at = 1.16, P > 0.05; ^bt = 10.12, P < 0.01.

Table 3 HCV NS5A and p21 promoter activity

Group	Relative luciferase activity	F	P
pwwp-luc (1.0 µg)	0.44 × 105	0.52	> 0.05
+ pCNS5A (0.5 µg)	0.46 × 105
+ pCNS5A (1.0 µg)	0.43 × 105
pwwp-luc (1.0 µg)	0.56 × 105	28.16	< 0.01
+ pC53-NS (0.5 µg)	2.68 × 105
+ pC53-NS (1.0 µg)	4.84 × 105